SREBF1

Sterol regulatory element-binding protein 1 · P36956 · SREBF1 on Sugi Atlas →

3,839 patent compounds predicted against SREBF1, 3,090 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4279559	1.00	2/20
Fatostatin (SCHEMBL2742732)	0.81	2/20
SCHEMBL4284101	0.78	2/20
SCHEMBL4282599	0.75	2/20
SCHEMBL6329780	0.68	2/20
SCHEMBL4286504	0.67	2/20
SCHEMBL4290927	0.67	2/20
SCHEMBL4292296	0.67	2/20
SCHEMBL4293604	0.67	2/20
SCHEMBL5044060	0.51	2/20
SCHEMBL4286677	0.42	2/20
Calcifediol Anhydrous (SCHEMBL3296)	1.00	1/20
Calcifediol Anhydrous (SCHEMBL156169)	1.00	1/20
Calcifediol Anhydrous (SCHEMBL263480)	1.00	1/20
T091317 (SCHEMBL457231)	1.00	1/20
Calcifediol Anhydrous (SCHEMBL1836573)	1.00	1/20
Calcifediol Anhydrous (SCHEMBL2734120)	1.00	1/20
Calcifediol Anhydrous (SCHEMBL3333455)	1.00	1/20
Calcifediol Anhydrous (SCHEMBL3333460)	1.00	1/20
SCHEMBL4285022	1.00	1/20

Clinical trials — most relevant to SREBF1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease	PHASE4	COMPLETED
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes	PHASE4	COMPLETED
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis	PHASE3	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation	PHASE2	UNKNOWN
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
The Sleep, Liver Evaluation and Effective Pressure Study	PHASE2	COMPLETED
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis	PHASE2	UNKNOWN
Statin Therapy and COVID-19 Infection	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Omics-based Predictors of NAFLD/Potential NASH	nan	UNKNOWN
Response to an Intervention With Omega-3 (RIO - Study)	nan	COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT	nan	COMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl	nan	COMPLETED
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)	nan	WITHDRAWN
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids	nan	RECRUITING
Micro RNA Levels in NAFLD	nan	UNKNOWN
The Role of Luteolin Supplementation in Cellular Metabolism of Myocytes and Fat Cells, Physical Performance, and Body Composition in Athletes.	nan	ENROLLING_BY_INVITATION
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)	nan	RECRUITING
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux	nan	COMPLETED
Genetic-specific Effects of Fructose on Liver Lipogenesis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SREBF1 binder may also engage these)

Protein	Name	Similarity
Q9WTN3	—	1.000	Q9WTN3 →
Q60416	—	0.999	Q60416 →
P56720	—	0.995	P56720 →
O97676	—	0.995	O97676 →
Q60698	—	0.982	Q60698 →
Q3TPJ7	—	0.982	Q3TPJ7 →
A2A8U2	—	0.981	A2A8U2 →
Q9TUG2	—	0.981	Q9TUG2 →
Q6NS60	—	0.979	Q6NS60 →
A2A9T0	—	0.979	A2A9T0 →
Q5SNT2	—	0.979	Q5SNT2 →
Q8C190	—	0.978	Q8C190 →
P24793	—	0.978	P24793 →
Q8CC12	—	0.978	Q8CC12 →
A7UA95	—	0.977	A7UA95 →
P12755	—	0.977	P12755 →
O15079	—	0.977	O15079 →
Q63379	—	0.976	Q63379 →
Q62925	—	0.976	Q62925 →
Q9Z125	—	0.976	Q9Z125 →
Q9NZQ3	—	0.975	Q9NZQ3 →
Q8VIP2	—	0.975	Q8VIP2 →
Q2VPU4	—	0.975	Q2VPU4 →
Q8BK03	—	0.974	Q8BK03 →
Q504T8	—	0.974	Q504T8 →
Q3UTZ3	—	0.974	Q3UTZ3 →
P59240	—	0.974	P59240 →
Q9Y2B5	—	0.974	Q9Y2B5 →
Q8TF61	—	0.974	Q8TF61 →
Q92622	—	0.974	Q92622 →